JP Morgan Maintains Neutral on Gentherm, Raises Price Target to $48
JP Morgan analyst Rajat Gupta maintains Gentherm (NASDAQ:THRM) with a Neutral and raises the price target from $41 to $48.
Read original at benzingaStocks · News reference
Gentherm Receives FDA 510(k) Clearance For Its Patented ThermAffyx Patient Safety System
Gentherm, a global market leader of innovative thermal management and pneumatic comfort technologies, announced today it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System. This Class II
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 8:01 PM
- Checked
- Jul 20, 2026, 8:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Stifel Maintains Buy on Gentherm, Raises Price Target to $59
Stifel analyst Nathan Jones maintains Gentherm (NASDAQ:THRM) with a Buy and raises the price target from $44 to $59.
Read original at benzinga12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Gainers Gentherm (NASDAQ:THRM) shares rose 21.3% to $43.74 during Thursday's regular session. The company's market cap stands at $1.1 billion. As per the news, the Q2 earnings report came out today. Fenbo
Read original at benzingaGentherm shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance with its midpoint above estimates. Also, the company approved a new $400 million stock buyback program.
Read original at benzinga